T-knife Therapeutics welcomes Laura Brege to its Board of Directors

– USA, CA –  T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, today announced the appointment of Laura Brege to its Board of Directors.

“We are excited to welcome Laura to our Board. Laura’s deep experience spans C-suite positions at multiple biotech companies, senior advisory and board roles and tenure as a venture capital investor. Her operational, development and strategic expertise will be valuable as we transition into the clinic early next year with our lead program targeting MAGE-A1 positive solid tumors,” said CEO, Tom Soloway.

About Laura Brege

Laura Brege serves on the boards of Acadia Pharmaceuticals, Inc., Mirum Pharmaceuticals, Inc., Pacira Pharmaceuticals, Inc., and HLS Therapeutics, Inc. She is also a Senior Advisor at BridgeBio Pharma, a clinical-stage biotechnology company developing novel, genetically targeted therapies. From 2012 to 2015, Ms. Brege served as CEO and President of Nodality, Inc., a privately-held biotechnology company focused on oncology and immunology. Previously, Ms. Brege held several senior-level positions at Onyx Pharmaceuticals, Inc. from 2006 to 2011 including EVP and COO. Before joining Onyx, Ms. Brege was a general partner at Red Rock Capital Management, a venture capital firm specializing in early-stage financing for technology companies. Before Red Rock, she was SVP T-knife Therapeutics and CFO at COR Therapeutics. Earlier in her career, Ms. Brege served as VP and CFO at Flextronics and VP and Treasurer of The Cooper Companies.

Ms. Brege commented, “I have worked on cancer therapeutics for several decades, and while the industry has made tremendous advances, there remains significant unmet medical need in the field of solid tumor therapy. I am impressed by the innovation being pursued at T-knife and eager to help advance their important mission.”

Ms. Brege earned her undergraduate degree from Ohio University and has an M.B.A. from the University of Chicago.

About T-knife Therapeutics

T-knife Therapeutics is a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, initially focused on T cell receptor engineered T cell therapies, a modality that holds the potential to generate transformative responses in patients with solid tumors. The Company’s unique approach leverages its proprietary HuTCR mouse platform, a next-generation T cell receptor and epitope discovery engine that produces fully human, tumor-specific TCRs, naturally selected in vivo for optimal affinity and high specificity.

T-knife is advancing a portfolio of TCR-T product candidates against targets with a high unmet medical need, including cancer-testis antigens, oncoviral antigens, and commonly shared tumor-driving neoantigens. T-knife was founded by leading T-cell and immunology experts using technology developed at the Max Delbruck Center for Molecular Medicine together with Charité – Universitätsmedizin Berlin.

For more information: https://t-knife.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team